Pharmacokinetics of an oral once-a-day controlled-release oxybutynin formulation compared with immediate-release oxybutynin

Oxybutynin is used for the treatment of urge urinary incontinence. In this randomized, open-label, two-way crossover, multiple-dose study, the pharmacokinetics of a once-daily, controlled-release formulation, OROS oxybutynin chloride, was compared with that of immediate-release (IR) oxybutynin (Ditropan). Thirteen healthy female volunteers received three 5 mg OROS oxybutynin chloride tablets once daily for 4 days or IR oxybutynin 5 mg administered every 8 hours for 4 days. On day 1, with OROS oxybutynin chloride, mean plasma concentrations rose slowly over approximately 6 hours following dosing (mean Cmax 4.2 ng/mL) and remained fairly constant over the 24-hour dosing interval, whereas with IR oxybutynin, mean plasma concentrations rose rapidly within the first hour after dosing (mean Cmax 12.0 ng/mL), then declined. The mean oxybutynin degree of fluctuation was much lower for OROS oxybutynin chloride (78%) than for IR oxybutynin (371%). For both formulations, the plasma concentration-time profiles for the metabolite N-desethyloxybutynin paralleled those of oxybutynin but at higher concentrations. Steady-state oxybutynin concentrations were achieved by day 3 for both formulations. Mean area under the concentration-time curve (AUC) values for both oxybutynin and its metabolite were similar between day 1 and day 4 for each treatment, suggesting time-invariant pharmacokinetics. With OROS oxybutynin chloride, mean relative bioavailability was higher (153%) for oxybutynin and lower (69%) for N-desethyloxybutynin compared with IR oxybutynin. This increased bioavailability may be due to reduced first-pass metabolism; within 3 to 5 hours after dosing, OROS systems are thought to reach the colon, where cytochrome P450-mediated oxidation (oxybutynin's primary metabolic pathway) may be less extensive than in the small intestine. Fewer subjects reported any adverse event with OROS oxybutynin chloride than with IR oxybutynin (including dry mouth, oxybutynin's most frequently reported anticholinergic adverse effect).
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				K. May, K. Westphal, T. Giessmann, D. Wegner, U. Adam, M. M. Lerch, R. Oertel, R. W. Warzok, W. Weitschies, M. Braeter, et al. Disposition and Antimuscarinic Effects of the Urinary Bladder Spasmolytics Propiverine: Influence of Dosage Forms and Circadian-Time Rhythms J. Clin. Pharmacol., May 1, 2008; 48(5): 570 - 579. [Abstract] [Full Text] [PDF]

				T. Oki, A. Toma-Okura, and S. Yamada Advantages for Transdermal over Oral Oxybutynin to Treat Overactive Bladder: Muscarinic Receptor Binding, Plasma Drug Concentration, and Salivary Secretion J. Pharmacol. Exp. Ther., March 1, 2006; 316(3): 1137 - 1145. [Abstract] [Full Text] [PDF]

				R. Dmochowski, A. Chen, G. Sathyan, S. MacDiarmid, S. Gidwani, and S. Gupta Effect of the Proton Pump Inhibitor Omeprazole on the Pharmacokinetics of Extended-Release Formulations of Oxybutynin and Tolterodine J. Clin. Pharmacol., August 1, 2005; 45(8): 961 - 968. [Abstract] [Full Text] [PDF]

				J. G. Ouslander Management of Overactive Bladder N. Engl. J. Med., February 19, 2004; 350(8): 786 - 799. [Full Text] [PDF]

				A. C. Diokno, R. A. Appell, P. K. Sand, R. R. Dmochowski, B. M. Gburek, I. W. Klimberg, S. H. Kell, and OPERA Study Group Prospective, Randomized, Double-Blind Study of the Efficacy and Tolerability of the Extended-Release Formulations of Oxybutynin and Tolterodine for Overactive Bladder: Results of the OPERA Trial Mayo Clin. Proc., June 1, 2003; 78(6): 687 - 695. [Abstract] [PDF]

				T. E. Lackner Advances in Managing Overactive Bladder Journal of Pharmacy Practice, August 1, 2000; 13(4): 277 - 289. [Abstract] [PDF]